Barclays Downgrades NUVL to Hold, Sets $124 Price Target
Barclays analyst Etzer Darout lowered NUVL's rating to hold with a $124 target, a 0.61% upside from the current price.
Key Points
- Barclays analyst Etzer Darout downgraded NUVL to a hold rating with a $124 price target on June 10, 2026.
- Barclays's $124 price target implies 0.61% upside from Nuvalent Inc's ($NUVL) current $123.25 share price.
- NUVL shares traded near $123.25, reflecting recent analyst downgrades across multiple firms.
- Insider transactions include sales by Chief Development Officer Darlene Noci and CEO James Richard Porter in early June 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Barclays analyst Etzer Darout has downgraded NUVL to a hold rating, setting a price target of $124. This change came on June 10, 2026, amid a wave of similar downgrades from other analysts. NUVL shares were trading around $123.25 at the time of the announcement.
Other Institutional Activity in NUVL
DEERFIELD MANAGEMENT COMPANY, L.P. maintained its position in NUVL with 17,248,450 shares valued at approximately $1.77 billion. FMR LLC reduced its holdings by 1,577,925 shares, ending with 9,274,959 shares worth about $950.2 million. Meanwhile, PARADIGM BIOCAPITAL ADVISORS LP increased its stake by 55,000 shares, holding a total of 5,324,433 shares valued at $545.5 million. BLACKROCK, INC. also raised its holdings slightly by 19,524 shares, bringing its total to 4,824,785 shares valued at $494.3 million. JPMORGAN CHASE & CO significantly boosted its position by 883,098 shares, totaling 3,088,349 shares worth $298.7 million.
Insider Buying and Selling at Nuvalent Inc
Recent insider transactions at NUVL include sales by Chief Development Officer Darlene Noci, who sold 20,000 shares on June 9, 2026, at an average price of $122.81 under a planned arrangement. Additionally, President and CEO James Richard Porter sold 30,000 shares on June 8, 2026, at an average price of $88.53, also under a planned sale.
Analysts Set New Price Targets
On June 10, 2026, TD Cowen, Barclays, UBS, and Guggenheim all downgraded NUVL to a hold rating, each setting a price target of $124. Similarly, Wells Fargo and HC Wainwright & Co. downgraded the stock to hold on June 9, 2026, with the same $124 price target. The consensus among analysts is a hold rating, with an average target price of $124 across the board.
About NUVL
NUVL operates in the healthcare sector, focusing on developing innovative treatments for serious diseases. The company is headquartered in the United States and is led by a team of experienced industry professionals. NUVL is committed to advancing medical science and improving patient outcomes through its research and development efforts.
Bottom Line
The recent downgrades by Barclays and other firms suggest a cautious outlook for NUVL, with a shared price target of $124. Investors should note that these analyst ratings reflect the firms' assessments as of June 2026 and may not represent future performance. It's important to consider these updates as part of a broader investment strategy.
Get Nuvalent Inc alerts
New 13F filings, insider trades, and analyst moves on $NUVL, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.